EHA 2024

June 13-16, 2024
Madrid, Spain

European Hematology Association Hybrid Congress 2024

Explore more Hematology-Oncology congress materials

Results(3)

Hematology-Oncology

A Randomized Comparison of CPX-351 and FLAG-Ida in High-Risk Myelodysplastic Syndrome (MDS): a Subgroup Analysis of UK NCRI AML19

Author(s): Alex Legg, Jazz Pharmaceuticals, Oxford, UK

Hematology-Oncology

Real-World Experience With CPX-351 Treatment for Acute Myeloid Leukemia in England: Updated Analysis of the Cancer Analysis System Database

Author(s): Alexandrina Lambova, IQVIA Inc., London, UK

Hematology-Oncology

Impact of Conditioning Intensity on Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Severity and Outcomes in Adult Hematopoietic Cell Transplant Patients: Results From the DEFIFrance Registry

Author(s): Mohamad Mohty, Hôpital St Antoine, Université Sorbonne, INSERM UMRS 938, Paris, France

Hematology-Oncology

Disclaimer

This AI model is continuing to learn and its responses are based on learned data patterns. It should not replace professional judgment. Please verify the information before use, and feedback is welcome to improve its accuracy.

Please do not include personal or confidential information in your searches. For information on how to report an adverse event or product complaint for a Jazz product, please visit: https://www.jazzpharma.com/medicines/drug-safety/.